Mechanism of Action of the Ribopyranoside Benzimidazole GW275175X against Human Cytomegalovirus
Open Access
- 1 May 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (5) , 1647-1651
- https://doi.org/10.1128/aac.48.5.1647-1651.2004
Abstract
New human cytomegalovirus (HCMV) therapies with novel mechanisms of action are needed to treat drug-resistant HCMV that arises during therapy with currently approved agents. 2-Bromo-5,6-dichloro-1-β-d-ribofuranosyl-1H-benzimidazole (BDCRB) is an effective anti-HCMV agent with a novel mechanism of action, but problems with in vivo stability preclude clinical development. A d-ribopyranosyl derivative of BDCRB, GW275175X, displays similar antiviral activity without the in vivo stability problems. We present an initial description of the activity of GW275175X against HCMV, other herpesviruses, and selected nonherpesviruses. In addition, we show that it acts as a DNA maturation inhibitor like the parent compound, BDCRB, rather than via the mechanisms of action of 1263W94 or any anti-HCMV drugs approved for marketing. GW275175X is a promising candidate for clinical development as an anti-HCMV agent.Keywords
This publication has 31 references indexed in Scilit:
- Synthesis and Antiviral Activity of Novel Erythrofuranosyl Imidazo[1,2-a]pyridine C-Nucleosides Constructed via Palladium Coupling of Iodoimidazo[1,2-a]pyridines and DihydrofuranJournal of Medicinal Chemistry, 2003
- The Human Cytomegalovirus UL97 Protein Kinase, an Antiviral Drug Target, Is Required at the Stage of Nuclear EgressJournal of Virology, 2003
- Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of ActionAntimicrobial Agents and Chemotherapy, 2002
- Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus ReplicationAntimicrobial Agents and Chemotherapy, 2002
- Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDSAmerican Journal of Ophthalmology, 2002
- ATPase Activity of the Terminase Subunit pUL56 of Human CytomegalovirusJournal of Biological Chemistry, 2002
- Phosphorylation of β-d-Ribosylbenzimidazoles Is Not Required for Activity against Human CytomegalovirusAntimicrobial Agents and Chemotherapy, 2002
- Cytomegalovirus treatment options in immunocompromised patientsExpert Opinion on Pharmacotherapy, 2001
- Synthesis of the First C3 Ribosylated Imidazo[1,2-a]pyridine C-Nucleoside by Enantioselective Construction of the Ribose MoietyThe Journal of Organic Chemistry, 1998
- Design, Synthesis, and Antiviral Activity of Certain 2,5,6-Trihalo-1-(.beta.-D-ribofuranosyl)benzimidazolesJournal of Medicinal Chemistry, 1995